Skip to main content

Advertisement

SpringerLink
Log in

Mastocytosis in Children

  • Pediatric Allergy and Immunology (W Dolen, Section Editor)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In this review, we examine the current understanding of the pathogenesis, clinical presentations, diagnostic tools, and treatment options of pediatric mastocytosis as well as the natural history of the disease.

Recent Findings

We discuss the emerging concept of mast cell activation syndrome.

Summary

Mastocytosis in children presents most commonly as isolated cutaneous lesions and is a relatively rare occurrence with excellent prognosis and spontaneous regression often occurring by adolescence. Systemic mastocytosis with organ system involvement is a more serious condition and is likely to persist into adulthood.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kambe N, Longley BJ, Miyachi Y, Kabashima K. KIT masters mast cells in kids, too. J Invest Dermatol. 2010;130:648–50.

    Article  CAS  PubMed  Google Scholar 

  2. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin N Am. 2014;34:283–95.

    Article  Google Scholar 

  3. Frieri M, Quershi M. Pediatric mastocytosis: a review of the literature. Pediatr Allergy Immunol Pulmonol. 2013;26:175–80.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Chantorn R, Shwayder T. Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. Pediatr Dermatol. 2012;29:605–9.

    Article  PubMed  Google Scholar 

  5. Uzzaman A, et al. Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009;53:629–34.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Huang A, Fiadorchanka N, Brar K, Balderacchi JL, Glick SA. In-utero presentation of aggressive systemic mastocytosis in a neonate. Br J Dermatol 2017; https://doi.org/10.1111/bjd.15506.

  7. Lanternier F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One. 2008;3:e1906.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Fried AJ, Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep. 2013;13:693–701.

    Article  CAS  PubMed  Google Scholar 

  9. •• Hartmann K, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35–45. This report describes the current classification of cutaneous mastocytosis and reviews prognostic considerations.

  10. Wiechers T, et al. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015;136:1581–1590.e3.

    Article  PubMed  Google Scholar 

  11. Onnes MC, Tanno LK, Elberink JN. Mast cell clonal disorders: classification, diagnosis and management. Curr Treat Options Allergy. 2016;3:453–64.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Piqueres-Zubiaurre T, Martinez de Lagran Z, Gonzalez-Perez R, Urtaran-Ibarzabal A, Perez de Nanclares G. Familial progressive hyperpigmentation, cutaneous mastocytosis, and gastrointestinal stromal tumor as clinical manifestations of mutations in the c-KIT receptor gene. Pediatr Dermatol. 2017;34:84–9.

    Article  PubMed  Google Scholar 

  13. Ben-Amitai D, Metzker A, Cohen HA. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J. 2005;7:320–2.

    PubMed  Google Scholar 

  14. Frieri M, Patel R, Celestin J. Mast cell activation syndrome: a review. Curr Allergy Asthma Rep. 2013;13:27–32.

    Article  CAS  PubMed  Google Scholar 

  15. Valent P, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood. 1992;80:2237–45.

    CAS  PubMed  Google Scholar 

  16. Kristensen T, Vestergaard H, Bindslev-Jensen C, Mortz CG, Kjaer HF, Ollert M, et al. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis. Allergy 2017; https://doi.org/10.1111/all.13187.

  17. Bodemer C, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130:804–15.

    Article  CAS  PubMed  Google Scholar 

  18. Longley BJ Jr, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A. 1999;96:1609–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ke H, Kazi JU, Zhao H, Sun J. Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis. Cell Biosci. 2016;6:55.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Brauns TC, Schultewolter T, Dissemond J, Maschke J, Goos M. C-KIT expression in primary cutaneous T-cell lymphomas. J Cutan Pathol. 2004;31:577–82.

    Article  PubMed  Google Scholar 

  21. Jawhar M, et al. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica. 2017;102:1035–43.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lee JW, et al. Aggressive systemic mastocytosis after germ cell tumor of the ovary: C-KIT mutation documentation in both disease states. J Pediatr Hematol Oncol. 2007;29:412–5.

    Article  CAS  PubMed  Google Scholar 

  23. Da Silva Figueiredo Celestino Gomes P, et al. Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication. PLoS One. 2014;9:e97519.

    Article  Google Scholar 

  24. Vaes M, Benghiat FS, Hermine O. Targeted treatment options in mastocytosis. Front Med (Lausanne). 2017;4:110.

    Article  Google Scholar 

  25. Gotlib J, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530–41.

    Article  CAS  PubMed  Google Scholar 

  26. Silver R, Curley JP. Mast cells on the mind: new insights and opportunities. Trends Neurosci. 2013;36:513–21.

    Article  CAS  PubMed  Google Scholar 

  27. •• Carter MC, et al. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol. 2015;136:1673–1679.e3. This report clarifies the clinical value of serum tryptase levels and bone marrow biopsy on management considerations.

  28. Hartmann K, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology. 2005;129:1042–6.

    Article  CAS  PubMed  Google Scholar 

  29. Wang HJ, Lin ZM, Zhang J, Yin JH, Yang Y. A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family. Clin Exp Dermatol. 2014;39:146–9.

    Article  PubMed  Google Scholar 

  30. Tang X, et al. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet. 2004;41:e88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Valent P, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603–25.

    Article  CAS  PubMed  Google Scholar 

  32. • Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140:349–55. This report describes the clinical features and diagnostic criteria of mast cell activation syndrome.

  33. Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin N Am. 2014;34:207–18.

    Article  Google Scholar 

  34. • Lyons JJ, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48:1564–9. This is the first report of a genetic condition with multisystem organ involvement and elevated basal serum tryptase level.

  35. Longley J, Duffy TP, Kohn S. The mast cell and mast cell disease. J Am Acad Dermatol. 1995;32:545–561; quiz 562-4.

    Article  CAS  PubMed  Google Scholar 

  36. Alvarez-Twose I, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy. 2012;67:813–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Alvarez-Twose I, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2012;157:275–80.

    Article  CAS  PubMed  Google Scholar 

  38. Moore C, Ehlayel MS, Junprasert J, Sorensen RU. Topical sodium cromoglycate in the treatment of moderate-to-severe atopic dermatitis. Ann Allergy Asthma Immunol. 1998;81:452–8.

    Article  CAS  PubMed  Google Scholar 

  39. Edwards AM, Capkova S. Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. BMJ Case Rep. 2011; https://doi.org/10.1136/bcr.02.2011.3910 (2011).

  40. Boyle RJ, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10:CD008838.

    PubMed  Google Scholar 

  41. • Matito A, et al. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol. 2015;167:47–56. This report clarifies the use of anesthetic agents with a decreased risk of triggering mast cell activation events in patients with mastocytosis.

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Allergy and Immunology, Virginia Commonwealth University Health Systems, 1000 E Broad Street, Richmond, VA, 23219, USA

    Nicholas Klaiber, Santhosh Kumar & Anne-Marie Irani

Authors
  1. Nicholas Klaiber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Santhosh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne-Marie Irani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne-Marie Irani.

Ethics declarations

Conflict of Interest

Dr. Irani reports receiving royalty payments from ThermoFisher for the tryptase assay and from Millipore, Santa Cruz, BioLegend, Hycult, and BioTech for antibodies used to identify mast cells and basophils. Drs. Klaiber and Kumar declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pediatric Allergy and Immunology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klaiber, N., Kumar, S. & Irani, AM. Mastocytosis in Children. Curr Allergy Asthma Rep 17, 80 (2017). https://doi.org/10.1007/s11882-017-0748-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-017-0748-4

Keywords

Search

Navigation